calgb 50801: pet adapted therapy in bulky stage i/ii hl
Published 3 years ago • 193 plays • Length 2:00Download video MP4
Download video MP3
Similar videos
-
3:05
the benefits of pet in the prognosis and treatment of hl
-
3:42
early pet-adapted treatment for hodgkin lymphoma: 10-year follow-up analysis
-
1:34
pet-guided treatment: the new standard of care in hodgkin lymphoma?
-
5:12
the current standard of care in advanced stage hl
-
1:17
the importance of risk-adapted therapies in hodgkin lymphoma
-
1:24
the changing landscape of btk inhibitor therapy in patients with mzl
-
1:22
diagnostics and treatment outcomes from primary cbcl
-
1:36
re-evaluating the role of radiation therapy in lymphoma & exploring combinations with immunotherapy
-
1:46
ivlbcl: a retrospective study
-
1:54
a novel clinical trial endpoint for acute gvhd
-
2:03
advances in pet & radiomics in lymphoma & insights into the international metabolic prognostic index
-
1:06
assessing metabolic tumor volume as a prognostic marker before car-t therapy for dlbcl
-
2:15
vipor: a multi-targeted therapy for the treatment of r/r dlbcl
-
1:34
molecular-guided treatment of b-cell lymphomas
-
1:33
btki inhibitors in the treatment of b-cell lymphoma - introduction
-
2:11
avenue window study: avelumab monotherapy followed by pet-adapted chemotherapy approach in chl
-
1:37
a prospective trial of radiation-free chemotherapy in high- and low-risk hl
-
2:39
new findings and challenges in the use of immunotherapy in hodgkin lymphoma
-
2:00
updates on treatment methods for hodgkin lymphoma